Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hughes Website

Marybeth S. Hughes, M.D., F.A.C.S.

Selected Publications

1)  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
A novel nomogram for peritoneal mesothelioma predicts survival.
Ann. Surg. Oncol. 20: 555-61, 2013.
2)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
3)  Erdag G, Chowdhuri SR, Fetsch P, Erickson D, Hughes MS, Filie AC.
KBA.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma.
Diagn. Cytopathol. [Epub ahead of print], 2013.
4)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma.
J. Clin. Oncol. [Epub ahead of print], 2013.
5)  Alvarez-Downing MM, Kamal N, Inchauste SM, Khangura SK, Malech HL, Holland SM, Hughes MS, Heller T, Sherry RM.
The role of surgery in the management of patients with refractory chronic granulomatous disease colitis.
Dis. Colon Rectum. 56: 609-14, 2013.
6)  Alexander HR, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y.
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.
Surgery. [Epub ahead of print], 2013.
7)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
8)  Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Clin. Cancer Res. 18: 2039-47, 2012.
9)  Nilubol N, Weinstein L, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E.
Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit?.
World J Surg. 36: 1368-74, 2012.
10)  Inchauste SM, Lanier BJ, Libutti SK, Phan GQ, Nilubol N, Steinberg SM, Kebebew E, Hughes MS.
Rate of Clinically Significant Postoperative Pancreatic Fistula in Pancreatic Neuroendocrine Tumors.
World J Surg. 36: 1517-26, 2012.
11)  Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ.
von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms.
Surgery. 152: 1106-17, 2012.
12)  Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E.
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
Surgery. 150: 1122-8, 2011.
13)  Venkatesan AM, Trivedi H, Adams KT, Kebebew E, Pacak K, Hughes MS.
Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas.
Surgery. 150: 1186-93, 2011.
14)  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Clin. Cancer Res. 17: 4550-7, 2011.
15)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011.
16)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
17)  Ge AX, Ryan ME, Giaccone G, Hughes MS, Pavletic SZ.
Acupuncture treatment for persistent hiccups in patients with cancer.
J Altern Complement Med. 16: 811-6, 2010.
18)  Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.
CD8+ enriched.
Clin. Cancer Res. 16: 6122-31, 2010.
19)  Mathur A, Kemp CD, Dutta U, Baid S, Ayala A, Chang RE, Steinberg SM, Papademetriou V, Lange E, Libutti SK, Pingpank JF, Alexander HR, Phan GQ, Hughes M, Linehan WM, Pinto PA, Stratakis CA, Kebebew E.
Consequences of Adrenal Venous Sampling in Primary Hyperaldosteronism and Predictors of Unilateral Adrenal Disease.
J Am Coll Surg. 211: 384-390, 2010.
20)  Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM.
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
J. Immunother. 33: 626-9, 2010.
21)  King KS, Darmani NA, Hughes MS, Adams KT, Pacak K.
Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma.
Endocrine. 37: 403-7, 2010.
22)  Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS.
Expression of Benign and Malignant Thyroid Tissue in Ovarian Teratomas and the Importance of Multimodal Management as Illustrated by a BRAF-Positive Follicular Variant of Papillary Thyroid Cancer.
Thyroid. 20: 981-7, 2010.
23)  Hong JJ, Schrump DS, Hughes MS.
Image of the month. Cystic parathyroid adenoma.
Arch Surg. 145: 705, 2010.
24)  Varghese S, Xu H, Bartlett D, Hughes M, Pingpank JF, Beresnev T, Alexander HR.
Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
Ann. Surg. Oncol. 17: 1870-7, 2010.
25)  Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I.
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
Ann. Surg. Oncol. 17: 163-70, 2010.
26)  Lodish MB, Adams KT, Huynh TT, Prodanov T, Ling A, Chen C, Shusterman S, Jimenez C, Merino M, Hughes M, Cradic KW, Milosevic D, Singh RJ, Stratakis CA, Pacak K.
Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl.
Endocr. Relat. Cancer. 17: 581-8, 2010.
27)  Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood. 114: 535-46, 2009.
28)  Capitini CM, Derdak J, Hughes MS, Love CP, Baird K, Mackall CL, Fry TJ.
Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation.
J. Pediatr. Hematol. Oncol. 31: 142-4, 2009.
29)  Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
J. Clin. Oncol. 26: 5233-9, 2008.
30)  Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S.
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
Cancer. 113: 293-301, 2008.
31)  Powell AC, Alexander HR, Pingpank JF, Steinberg SM, Skarulis M, Bartlett DL, Agarwal S, Cochran C, Seidel G, Fraker D, Hughes MS, Jensen RT, Marx SJ, Libutti SK.
The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism.
Surgery. 144: 878-83; discussion 883-4, 2008.
32)  Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA.
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clin. Cancer Res. 14: 5610-8, 2008.
33)  Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA.
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
Clin. Cancer Res. 13: 6681-8, 2007.
34)  Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE.
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
J. Immunother. 29: 224-31, 2006.
35)  Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science. 314: 126-9, 2006.
36)  Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
J. Clin. Oncol. 24: 2283-9, 2006.
37)  Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM.
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Immunother. 28: 593-8, 2005.
38)  Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA.
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.
J. Immunol. 175: 7226-34, 2005.
39)  Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA.
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
Hum. Gene Ther. 16: 457-72, 2005.
40)  Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM.
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
J. Immunol. 175: 6169-76, 2005.
41)  Feldman ED, Hughes MS, Stratton P, Schrump DS, Alexander HR.
Pseudo-Meigs' syndrome secondary to isolated colorectal metastasis to ovary: a case report and review of the literature.
Gynecol. Oncol. 93: 248-51, 2004.
42)  Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA.
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
J. Immunol. 171: 3287-95, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/15/2013.